Search Results 1311-1320 of 16381 for alt

1. A Study of RP2 with Nivolumab compared to Ipilimumab with Nivolumab with Metastatic Uveal Melanoma - Mayo Clinic

   Aspartate aminotransferase (AST) and alanine aminotransferase increased (ALT) ≤ 3.0 × ULN; Alkaline phosphatase (ALP) ≤ 2.5 × ULN. Has adequate renal ...

2. S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer - Mayo Clinic

   Adequate hepatic function as evidenced by bilirubin ≤ 2 x institutional upper limit of normal (ULN), SGOT (AST) and SGPT (ALT) ≤ 3 x institutional ULN, or ...

3. Highlights of a healthy living cooking demonstration - Mayo Clinic

   Appointments at Mayo Clinic. Mayo Clinic offers appointments in Arizona, Florida and Minnesota and at Mayo Clinic Health System locations.

4. A Study Evaluating AMG 424 in Subjects With Multiple Myeloma - Mayo Clinic

   aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3x upper limit of normal (ULN);; total bilirubin < 1.5 x ULN (unless considered due to ...

5. A Study to Evaluate the Safety and Effectiveness of Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia - Mayo Clinic

   Alanine aminotransferase (ALT) > 3 × ULN;; Total bilirubin > 1.5 × ULN unless due to a documented diagnosis of Gilbert's syndrome. Have any of the following ...

6. Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery - Mayo Clinic

   Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN; Serum creatinine =< 1.5 X institutional ULN and creatinine clearance >= 60 ...

7. Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III - Mayo Clinic

   ... ALT or AST > 2.5 x UNL or other hepatic abnormalities that in the opinion of the investigator would preclude the subject from participation in the study.

8. An Extension Study to Evaluate the Long-Term Safety and Tolerability of NEOD001 for Treatment of People with Light Chain Amyloidosis - Mayo Clinic

   ... (ALT) ≤3 × ULN; Estimated glomerular filtration rate ≥30 mL/minute. Seated systolic blood pressure 90 to 180 mmHg; ECOG Performance Status 0 to 2; Women of ...

9. Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma - Mayo Clinic

   Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 ULN. Participating Mayo Clinic locations. Study statuses change often. Please contact ...

10. A Study to Compare Nivolumab or Brentuximab Vedotin Plus Combination Chemotherapy to Treat Patients with Newly-diagnosed Stage III-IV Classic Hodgkin Lymphoma - Mayo Clinic

    Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x IULN (must be documented within 28 days prior to registration for adults [age 18 ...